These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21904603)

  • 21. Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) as a Target for Concurrent Management of Diabetes and Obesity-Related Cancer.
    Wang Q; Imam MU; Yida Z; Wang F
    Curr Pharm Des; 2017; 23(25):3677-3688. PubMed ID: 28677503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of peroxisome proliferator activated receptor γ regulation by non-steroidal anti-inflammatory drugs.
    Puhl AC; Milton FA; Cvoro A; Sieglaff DH; Campos JC; Bernardes A; Filgueira CS; Lindemann JL; Deng T; Neves FA; Polikarpov I; Webb P
    Nucl Recept Signal; 2015; 13():e004. PubMed ID: 26445566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists.
    Kaserer T; Obermoser V; Weninger A; Gust R; Schuster D
    Eur J Med Chem; 2016 Nov; 124():49-62. PubMed ID: 27560282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oroxyloside prevents dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB pathway through PPARγ activation.
    Wang X; Sun Y; Zhao Y; Ding Y; Zhang X; Kong L; Li Z; Guo Q; Zhao L
    Biochem Pharmacol; 2016 Apr; 106():70-81. PubMed ID: 26947454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and Characterization of Cannabimovone, a Cannabinoid from
    Iannotti FA; De Maio F; Panza E; Appendino G; Taglialatela-Scafati O; De Petrocellis L; Amodeo P; Vitale RM
    Molecules; 2020 Mar; 25(5):. PubMed ID: 32138197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
    ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computational modeling-based discovery of novel classes of anti-inflammatory drugs that target lanthionine synthetase C-like protein 2.
    Lu P; Hontecillas R; Horne WT; Carbo A; Viladomiu M; Pedragosa M; Bevan DR; Lewis SN; Bassaganya-Riera J
    PLoS One; 2012; 7(4):e34643. PubMed ID: 22509338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease.
    Bassaganya-Riera J; Hontecillas R
    Curr Opin Clin Nutr Metab Care; 2010 Sep; 13(5):569-73. PubMed ID: 20508519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virtual Screening as a Technique for PPAR Modulator Discovery.
    Lewis SN; Bassaganya-Riera J; Bevan DR
    PPAR Res; 2010; 2010():861238. PubMed ID: 19746174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mode of peroxisome proliferator-activated receptor γ activation by luteolin.
    Puhl AC; Bernardes A; Silveira RL; Yuan J; Campos JL; Saidemberg DM; Palma MS; Cvoro A; Ayers SD; Webb P; Reinach PS; Skaf MS; Polikarpov I
    Mol Pharmacol; 2012 Jun; 81(6):788-99. PubMed ID: 22391103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nitrated oleic acid up-regulates PPARgamma and attenuates experimental inflammatory bowel disease.
    Borniquel S; Jansson EA; Cole MP; Freeman BA; Lundberg JO
    Free Radic Biol Med; 2010 Feb; 48(4):499-505. PubMed ID: 19932165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
    Gao Q; Hanh J; Váradi L; Cairns R; Sjöström H; Liao VW; Wood P; Balaban S; Ong JA; Lin HY; Lai F; Hoy AJ; Grewal T; Groundwater PW; Hibbs DE
    Bioorg Med Chem; 2015 Dec; 23(24):7676-84. PubMed ID: 26616289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validation.
    Guasch L; Sala E; Castell-Auví A; Cedó L; Liedl KR; Wolber G; Muehlbacher M; Mulero M; Pinent M; Ardévol A; Valls C; Pujadas G; Garcia-Vallvé S
    PLoS One; 2012; 7(11):e50816. PubMed ID: 23226391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peroxisome proliferator-activated receptor gamma in the colon: inflammation and innate antimicrobial immunity.
    Speca S; Dubuquoy L; Desreumaux P
    J Clin Gastroenterol; 2014; 48 Suppl 1():S23-7. PubMed ID: 25291120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory Bowel Disease: New Insights into the Interplay between Environmental Factors and PPARγ.
    Caioni G; Viscido A; d'Angelo M; Panella G; Castelli V; Merola C; Frieri G; Latella G; Cimini A; Benedetti E
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel PPARγ partial agonists with weak activity and no cytotoxicity; identified by a simple PPARγ ligand screening system.
    Cho MC; Lee DH; Kim EJ; Lee JY; Kang JW; Song JH; Chong Y; Kim Y; Hong JT; Yoon DY
    Mol Cell Biochem; 2011 Dec; 358(1-2):75-83. PubMed ID: 21681413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of Peroxisome Proliferator-Activated Receptor (PPAR) Alpha and Gamma Agonists Prevents Corneal Inflammation and Neovascularization in a Rat Alkali Burn Model.
    Nakano Y; Arima T; Tobita Y; Uchiyama M; Shimizu A; Takahashi H
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32707656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
    Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
    J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes.
    Pang T; Benicky J; Wang J; Orecna M; Sanchez-Lemus E; Saavedra JM
    J Hypertens; 2012 Jan; 30(1):87-96. PubMed ID: 22124178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach.
    D'Aniello E; Fellous T; Iannotti FA; Gentile A; Allarà M; Balestrieri F; Gray R; Amodeo P; Vitale RM; Di Marzo V
    Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):586-597. PubMed ID: 30611848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.